Selective Orexin Receptor Antagonists as Novel Augmentation Treatments for Major Depressive Disorder: Evidence for Safety and Efficacy From a Phase 2B Study of Seltorexant

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Fingerprint

Dive into the research topics of 'Selective Orexin Receptor Antagonists as Novel Augmentation Treatments for Major Depressive Disorder: Evidence for Safety and Efficacy From a Phase 2B Study of Seltorexant'. Together they form a unique fingerprint.

Medicine & Life Sciences